Has anyone emailed the company about this and had a response? I sent one the other day but they're so ignorant they NEVER respond to emails.
Good News -- I just called Aderans Research Institute in Atlanta
Collapse
X
-
Maybe he's trying to soften the blow of the news but that was his opinion. I personally would not get my hopes up for any of these companies (ARI, Replicel, Histogen) until they show something more concrete.
It's not owned by a multi-million $ enterprise anymore. Aderans has cut all the funding. ARI is off on their own now it seems.Comment
-
LOL@"making waves in Hawaii":
Also, STILL NO FORMAL PUBLIC ANNOUNCEMENT ON THEIR WEBSITE. It's disgraceful behaviour, we're hearing about this through a phone call to a radio host, how unprofessional of them.Comment
-
Comment
-
Actually, that's not funny:
It took them 11 years to find out what Dr. Gho found out (under high pressure) within a few years.
"Cell-based therapy" ...yeah, sure ...Comment
-
Comment
-
-
Hard to be super negative when it's not like they showed amazing results in the first place.
They had an intriguing product but never really did anything, I'm not gonna be depressed over a product that barely showed results in the first place.
now if Histogen all of sudden collapsed I'd be mad, because it seems like they have at least somewhat of a working product.Comment
-
I totally agree. Maybe in 2004 I would have put a lot of hope in them. But now, who cares, I can't see how anyone could have cared after what they (didn't) show last year.
Go FollicaComment
-
Joke company, with disgraceful communication skills!
Are they that much of a loss?
Hopefully if Ji Gami does continue it will be run by a company that's a bit more open and honest.Comment
-
More important is the release date... they had plans for next year to have a commercial product.Comment
-
Comment
-
So now...mass suicide?
This was by far the best funded, and most sophisticated operation. Replicel is a joke compared to ARI.
Unless Nigam can figure it out, we're going to be waiting for many many years gentlemen. (I'm ignoring Follica as I have no knowledge of them).
MPB just doesn't have the pipeline to justify any optimism. No large pharma invests in MPB, the rest is left to tiny operations like Follica or Replicel and a wig company funding ARI.Comment
Comment